Copanlisib - Aliqopa (USA)
According to the NCI website Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitorwith potential antineoplastic activity.
Indication according to the PDR:
- Used in adults with relapsed follicular lymphoma
Severe hyperglycemia and hypertension have been reported
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health